European expansion and new product introductions have delivered continued growth in 2015
Touch Bionics, a provider of world-leading upper limb prosthetic technologies, said its preliminary results indicate the company achieved total revenue of £15 million in 2015, an increase of 11 per cent over 2014.
Touch Bionics’ growth was driven by strong results from its European markets, most notably in Germany, and also in France, where the i-limb is now officially approved and funded by the French governmental health authorities.
“We are pleased with our 2015 performance and are proud that there have now been more than 5,000 i-limb wearers fitted world-wide”. said Ian Stevens, CEO, Touch Bionics.
“In 2015, we introduced the i-limb quantum and i-digits quantum hands, both of which can be controlled using simple gestures and are stronger and faster than their predecessors. We anticipate continued growth from sales of these electronic prosthetic hands and partial hands in 2016”.
Touch Bionics is a provider of world-leading prosthetic technologies designed to achieve positive outcomes for people with upper limb deficiencies.
Touch Bionics was the first company to develop an electrically powered prosthetic hand with five independently powered fingers and the company continues to be a pioneer in upper limb prosthetics.
The company’s products include electronic prosthetic hand and prosthetic fingers, as well as passive silicone prostheses that closely match the natural appearance of the wearer.
A spin-out from the UK’s National Health Service, Touch Bionics was founded by inventor David Gow and is funded and supported by Archangel Investors Limited and Scottish Enterprise.
